



OPEN ACCESS

EDITED AND REVIEWED BY
Johannes le Coutre,
University of New South Wales, Australia

*CORRESPONDENCE
Simin N. Meydani
✉ simin.meydani@tufts.edu

†PRESENT ADDRESSES

Erin D. Lewis,
KGK Science, Inc., London, Ontario, ON,
Canada

Weimin Guo,
Department of Pathology and Laboratory
Medicine, Boston University Chobanian &
Avedisian School of Medicine, Boston, MA,
United States

Dora Pereira,
Vifor Pharma UK Ltd., Cambridge, England,
United Kingdom

RECEIVED 25 January 2024

ACCEPTED 12 February 2024

PUBLISHED 27 February 2024

CITATION

Lewis ED, Ortega EF, Dao MC, Barger K,
Mason JB, Leong JM, Osburne MS, Magoun L,
Nepveux V FJ, Chishti AH, Schwake C,
Quynh A, Gilhooly CH, Petty G, Guo W,
Matuszek G, Pereira D, Reddy M, Wang J,
Wu D, Meydani SN and Combs GF Jr (2024)
Corrigendum: Safe and effective delivery of
supplemental iron to healthy adults: a
two-phase, randomized, double-blind trial –
the safe iron study. *Front. Nutr.* 11:1376599.
doi: 10.3389/fnut.2024.1376599

COPYRIGHT

© 2024 Lewis, Ortega, Dao, Barger, Mason,
Leong, Osburne, Magoun, Nepveux V, Chishti,
Schwake, Quynh, Gilhooly, Petty, Guo,
Matuszek, Pereira, Reddy, Wang, Wu, Meydani
and Combs. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Safe and effective delivery of supplemental iron to healthy adults: a two-phase, randomized, double-blind trial – the safe iron study

Erin D. Lewis^{1†}, Edwin F. Ortega¹, Maria Carlota Dao¹,
Kathryn Barger¹, Joel B. Mason¹, John M. Leong²,
Marcia S. Osburne², Loranne Magoun², Felix J. Nepveux V²,
Athar H. Chishti³, Christopher Schwake³, Anh Quynh³,
Cheryl H. Gilhooly¹, Gayle Petty¹, Weimin Guo^{1†},
Gregory Matuszek¹, Dora Pereira^{4†}, Manju Reddy⁵, Jifan Wang¹,
Dayong Wu¹, Simin N. Meydani^{1*} and Gerald F. Combs Jr.¹

¹Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, United States, ²Department of Molecular Biology and Microbiology, Tufts University, Boston, MA, United States, ³Department of Developmental, Molecular and Chemical Biology, Tufts University, Boston, MA, United States, ⁴Department of Pathology, University of Cambridge, Cambridge, United Kingdom, ⁵Department of Food Science and Human Nutrition, Iowa State University, Ames, IA, United States

KEYWORDS

iron, ferrous sulfate, malarial infectivity, bacterial proliferation, gut inflammation, IHAT, fungal iron

A corrigendum on

Safe and effective delivery of supplemental iron to healthy adults: a two-phase, randomized, double-blind trial – the safe iron study

by Lewis, E. D., Ortega, E. F., Dao, M. C., Barger, K., Mason, J. B., Leong, J. M., Osburne, M. S., Magoun, L., Nepveux, V. F. J., Chishti, A. H., Schwake, C., Quynh, A., Gilhooly, C. H., Petty, G., Guo, W., Matuszek, G., Pereira, D., Reddy, M., Wang, J., Wu, D., Meydani, S. N., and Combs, G. F. (2023). *Front. Nutr.* 10:1230061. doi: 10.3389/fnut.2023.1230061

In the published article, there was an error. The error involved an inconsistency between our abstract and discussion regarding the observed effects of one treatment on some secondary outcomes, GI symptoms.

A correction has been made to **Abstract, subsection Results**.

This section previously stated:

“Supplementation with any form of iron did not affect any primary endpoint. In Phase I, the frequency of gastrointestinal symptoms associated with FS was unaffected by dosing with MNP or weekly administration; but participants taking IHAT more frequently reported abdominal pain (27%, $p < 0.008$) and nausea (4%, $p = 0.009$) than those taking

FS, while those taking ASP more frequently reported nausea (8%, $p = 0.009$). Surprisingly, only 9% of participants taking IHAT at 120 mg Fe/day (Phase II) reported abdominal pain and no other group reported that symptom.”

The corrected section appears below:

“Supplementation with any form of iron did not affect any primary endpoint. Regarding secondary endpoints, in Phase I participants taking IHAT more frequently reported abdominal pain (27%, $p = 0.008$) than other iron forms; those taking the weekly FS dose more frequently reported nausea (20%, $P = 0.009$) than the other forms and modes of administration. In phase II, no such differences were observed.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.